Titre :

Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review

Auteur(s) :

Savina, Marion [Auteur]
CIC Bordeaux
Gourgou, Sophie [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Italiano, Antoine [Auteur]
Institut Bergonié [Bordeaux]
Dinart, Derek [Auteur]
Institut Bergonié [Bordeaux]
Rondeau, Virginie [Auteur]
Institut de Santé Publique, d'Epidémiologie et de Développement [ISPED]
Penel, Nicolas [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Mathoulin-Pelissier, Simone [Auteur]
CIC Bordeaux
Bellera, Carine A. [Auteur]
CIC Bordeaux

Titre de la revue :

Critical Reviews in Oncology/Hematology

Nom court de la revue :

Crit. Rev. Oncol. Hematol.

Numéro :

123

Pagination :

21-41

Date de publication :

2018-03

ISSN :

1879-0461

Mot(s)-clé(s) en anglais :

Cancer
Overall survival
Surrogate endpoint
Systematic review
Randomized controlled trial
Meta-analysis

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: In cancer randomized controlled trials (RCT), alternative endpoints are increasingly being used in place of overall survival (OS) to reduce sample size, duration and cost of trials. It is necessary to ensure ...
Lire la suite >BACKGROUND: In cancer randomized controlled trials (RCT), alternative endpoints are increasingly being used in place of overall survival (OS) to reduce sample size, duration and cost of trials. It is necessary to ensure that these endpoints are valid surrogates for OS. Our aim was to identify meta-analyses that evaluated surrogate endpoints for OS and assess the strength of evidence for each meta-analysis (MA). METHODS: We performed a systematic review to identify MA of cancer RCTs assessing surrogate endpoints for OS. We evaluated the strength of the association between the endpoints based on (i) the German Institute of Quality and Efficiency in Health Care guidelines and (ii) the Biomarker-Surrogate Evaluation Schema. RESULTS: Fifty-three publications reported on 164 MA, with heterogeneous statistical methods Disease-free survival (DFS) and progression-free survival (PFS) showed good surrogacy properties for OS in colorectal, lung and head and neck cancers. DFS was highly correlated to OS in gastric cancer. CONCLUSIONS: The statistical methodology used to evaluate surrogate endpoints requires consistency in order to facilitate the accurate interpretation of the results. Despite the limited number of clinical settings with validated surrogate endpoints for OS, there is evidence of good surrogacy for DFS and PFS in tumor types that account for a large proportion of cancer cases.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T18:18:02Z
2024-05-24T11:09:43Z